CategoryCOVID-19

#MSCOVID19: a call to arms

Barts-MS rose-tinted-odometer: ★★★ Black and Gray Hurricane Friday, #000000 #d3d3d3 I was kindly invited by David Martin the CEO of the MS Trust to participate in a  Parliamentary round table meeting on Multiple Sclerosis on Tuesday. The meeting was chaired by Helen Hayes MP, who impressed me immensely and reassured me that the Labour party has some serious talent and committed MPs on the...

#MSCOVID19 and anti CD20 and covid-19 vaccination responses. More of the same. T cell responses not affected, so what does this say about how anti-CD20 works in MS?

More of the same….anti-CD20 inhibits seroconversion, but there is a T cell response. Even if there is an antibody response it is of lower quality. Get vaccinated before anti-CD20 and the vaccine response is like controls. Time matters and the longer the interval between dose and vaccine more response. So I think it is safe to say we know this already….but prepared this has not...

The King has not left the Building and is Back Again within a Week..Antibody responses on anti-CD20 and delays

Dr. Marton König (i.e. King in Norwegian) appeared on the blog earlier this week and is back again, to further show you what I have been saying for months. “If you want to optimise your antibody response on ocrelizumab you need to consider a delay”. This study is from the next-door neighbour of rituxiland and shows that if you are on rituximab it is perhaps worth considering a delay...

#MSCOVID19 Third Dose Boostsers. A little, I mean only a little better for ani-CD20 but not for fingolimod.

Apologises for interupting NDG day, but I think it is important news. I know you are all bored with COVID-19 but you have choices to make and therefore you need data. Here is some third dose-booster data (100 using rituximab, 1 ocrelizumab, and 29 fingolimod) and as I have predicted it is not good reading. Although some people who did not make a response after 2 doses made a response after 3, the...

#MSCOVID19 vaccines 6 months on

This the follow-up from Israel on the Vaccine study looking at 6 month follow-up ocrelizumab and fingolimod never got going maybe there is a drop with other DMT around 6 months and supports the view that boosters should be taken to boost protective antibody levels. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Dolev M, Menascu S, Magalashvili D, Flechter S, Givon U, Guber D, Sonis P, Zilkha...

MSCOVID19 The beta interferon experience

As you may realise I don’t report to much on CRAB drugs, because I am not a big fan. Sure they are useful for some people but for many they do not work well enough. We all know this because pharma do trials against them these days, There they know their new-kid-on-the-block drug will do better. You know my opinions about this. However there is some good news in relation to COVID-19...

COVIDtriMS2021

The manufacturers of anti-CD20 antibodies have late breakers suggesting that severity in anti-CD20 depleted MSers is a reflection of factors that affect the general population including age and co-morbidities. The question is whether this message sticks or whether it is the message from a few academic papers that there is a small increased risk of increased severity is the influencer. The message...

#MSCOVID19. Way to Make Vaccines Better: A Mousey View and the iMods from COVIDtriMS2021

What has this got to do with MS..Nothing…..Sort-of Lab Lessons Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice Paschall, A. V., Ozdilek, A., Briner, S. L., Brindley, M. A., Avci, F.10.1101/2021.09.28.462156 — Posted: 2021-09-30 Significance Statement Immunosuppressant regimens are widely used as therapies for a variety of diseases...

#COVID19MS: antibodies matter

Barts-MS rose-tinted-odometer: ★★★  (An ECTRIMS red Wednesday #e52330) I am getting endless questions about when is it the best time to have the 3rd and/or booster dose of the COVID-19 vaccine in relation to ocrelizumab infusions, which is why I did an MS-Selfie Case Study on this topic on the weekend.  Unfortunately, until we have good evidence that shows people on ocrelizumab who seroconvert do...

#MSCOVID19.Delaying ocrelizumab dose to let B cells repopulate is not associated with disease activation.

There are two questions (1) If one continues to take ocrelizumab, will the T cell immunity following COVID-19 vaccination be enough to stop severe COVID-19. (2) Is it safe to miss a dose to allow B cells to repopulate to allow a B cell-vaccine response. We dont have a definative answer yet for number 1, but we know that it will not necessarily stop you getting symptomatic COVID-19, and severe...

Translate

Categories

Recent Posts

Recent Comments

Archives